GlassScriptPhysician profile
Jackline S Joseph
NPI 1407889173
$8,886.36
in general payments reported to CMS, 2019-2025
44 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $926 · 2021: $1,141 · 2022: $1,111 · 2023: $1,757 · 2024: $1,517 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,778.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $1,313.48 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $871.41 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $605.75 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $506.45 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Shield Therapeutics INC | $325.12 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $281.30 | 2019-2022 | |
| Amarin Pharma, INC. | $223.28 | 2020-2021 | |
| Ibsa Pharma INC. | $209.17 | 2022-2025 | Licart, Tirosint, Flector |
| Lilly USA, LLC | $190.32 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $168.33 | 2024-2025 | Voquezna |
| Pfizer INC. | $156.49 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.32 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $150.76 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $150.00 | 2023 | Acthar |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $150.00 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.05 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $110.43 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $109.86 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $109.17 | 2023-2024 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $102.77 | 2022 | |
| Glaxosmithkline, LLC. | $89.73 | 2019-2025 | Rotarix, Bexsero, Pediarix |
| Genentech USA, INC. | $88.95 | 2019-2021 | |
| Sanofi Pasteur INC. | $81.05 | 2021-2024 | |
| Gilead Sciences, INC. | $80.39 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $77.88 | 2019-2022 | |
| Amgen INC. | $73.87 | 2023-2025 | Krystexxa, Evenity, Prolia |
| Allergan, INC. | $71.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $67.84 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $65.85 | 2022-2024 | Quviviq |
| Seqirus USA INC | $59.67 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Dexcom, INC. | $50.10 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.22 | 2019 | |
| Axsome Therapeutics, INC. | $37.63 | 2023-2025 | Sunosi, Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.38 | 2019-2021 | |
| Boston Scientific Corporation | $35.53 | 2023 | Watchman |
| Mayne Pharma Commercial LLC | $27.27 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.95 | 2022 | |
| Mylan Specialty L.P. | $17.66 | 2022 | |
| Biogen, INC. | $17.28 | 2024 | Skyclarys |
| Avion Pharmaceuticals | $14.62 | 2021 | |
| Linus Health, INC. | $13.71 | 2024 | Core Cognitive Evaluation |
| Viatris Specialty LLC | $13.57 | 2025 | Yupelri |
| Hikma Pharmaceuticals USA | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackline Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.